STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 04:08 PM

Longeveron Q1 Net Loss $(4.7)M; Cash $15.8M; Going Concern Doubt

AI Summary

Longeveron reported a net loss of $(4.7) million for the first quarter of 2026, an improvement from $(5.0) million in the same period last year. Cash and cash equivalents significantly increased to $15.8 million as of March 31, 2026, up from $4.7 million at December 31, 2025, primarily driven by $13.4 million from common and preferred stock issuance and $1.3 million from warrant exercises. Despite the increased cash, the company's cash flow forecast indicates insufficient funds to meet minimum expenditure commitments for one year, raising substantial doubt about its ability to continue as a going concern. Total revenues saw a slight increase to $398k, while operating expenses decreased.

Key Highlights

  • Net loss for Q1 2026 was $(4.7) million, an improvement from $(5.0) million in Q1 2025.
  • Basic and diluted net loss per share improved to $(0.19) from $(0.34) year-over-year.
  • Cash and cash equivalents increased to $15.8 million as of March 31, 2026, from $4.7 million at December 31, 2025.
  • Proceeds from common and preferred stock issuance, net of costs, totaled $13.4 million.
  • Proceeds from warrants exercised, net of costs, amounted to $1.3 million.
  • Total revenues for Q1 2026 were $398k, a slight increase from $381k in Q1 2025.
  • Total operating expenses decreased to $5.0 million in Q1 2026 from $5.5 million in Q1 2025.
  • Substantial doubt exists about the company's ability to continue as a going concern.
LGVN
Biotechnology: Pharmaceutical Preparations
Longeveron Inc.

Price Impact